HDO Health News
HDO Health was Featured on The Ohio State University College of Engineering Website
HDO HEALTH ADDS EXPERIENCED MEDICAL DEVICE EXECUTIVE, ENTREPRENEUR, INVESTOR, AND
DIRECTOR TO BOARD
Andrew Cothrel brings 30+ years of healthcare and medical device experience to support HDO Health in
achieving its mission to bring life-saving medical devices to the world.
May 5, 2022 - HDO Health is excited to announce participation in the 2022 Spring Ohio State Technology Showcase hosted by the Keenan Center for Entrepreneurship on Thursday May 19, 2022 from 5 - 7 pm EST at the Idea Foundry, 421 W. State Street, Columbus, OH 43215.
HDO Health Featured on the Rev1 Ventures Blog
HDO Health Selected as a Summer 2022 Cohort Company for the Wheeler and Wolstein Internship Program
March 18, 2022 - HDO Health is excited to announce its selection as a participant company for the 2022 Cohort of The Ohio State University Keenan Center for Entrepreneurship Wheeler and Wolstein Internship Program.
HDO Health Awarded a Phase 2 Ohio Department of Development Technology Validation and Startup Fund (TVSF) Grant
March 15, 2022 - HDO Health was recently awarded a Technology Validation and Startup Fund (TVSF) Phase 2 Grant from Ohio Third Frontier. Ohio Third Frontier is an internationally recognized, technology-based economic development initiative that is successfully changing the trajectory of Ohio’s economy. Third Frontier works with innovative startup companies across the state, making Ohio the destination for technology entrepreneurs. This robust network of resources helps take advanced ideas and turn them into new technology businesses.
HDO Health will be utilizing the non-dilutive grant funds to further develop and finalize the design for their innovative junctional tourniquet (The Journiquet™) and prepare for a Class II U.S. Federal Drug Administration (FDA) 510(k) filing and clearance as well as other company infrastructure and commercialization activities.
HDO Health Announces Selection for Engagement with the Rev1 Ventures Startup Studio
June 29, 2021 - HDO Health is proud to announce that they have been selected for an initial engagement as part of the Rev1 Ventures startup studio. Rev1 Ventures is a unique investor startup studio that helps startups scale and corporates innovate. This engagement includes the pairing of the HDO Health founding team with a team of start-up advisors. In addition, it provides free access to significant learning resources, service providers, and a network of other entrepreneurs leading high-growth companies. This strategic partnership connects HDO Health to the talent, customers, space, and funding we need — when we need it.
HDO Health Successfully Completes Phase 1 Ohio Department of Development Technology Validation and Startup Fund (TVSF) Grant Cycle
May 13, 2021 - The HDO Health team recently completed a TVSF Phase 1 funding and development cycle. The goal of the TVSF Phase 1 was to advance the design and fabricate functional prototypes in preparation for future demonstrations and operational testing of the HDO Health junctional tourniquet (the Journiquet). The objectives were to take the design through Technology Readiness Level (TRL) 6 with a system prototype demonstrated in a laboratory environment on a medical manikin with experienced users. The project results included capturing and documenting user requirements for a minimally viable product (MVP), fabrication of mock-ups of the preliminary design to support usability sessions conducted with military and EMT personnel to gather user inputs on requirements and product design. Using the outputs of the usability sessions, along with the generation of a design specification traceability matrix, a detailed engineering design of the device to include ergonomic and anthropometric design factors was completed. This work led to the fabrication of fully functional engineering prototypes for laboratory bench-top testing and a second usability session. Feedback from the second usability session conducted at the Ohio State University Clinical Skills Education and Assessment Center (CSEAC) informed the development of a comprehensive user requirements document and production of (v2) functional prototypes ready for perfused cadaver studies and other testing required for a FDA 510(k) submission.